Anaplastic carcinoma of the thyroid gland

Textbook of Endocrine Surgery

Volumn , Issue , 2005, Pages 159-167

  Rosen, Irving B ^a,b   Asa, Sylvia L ^c   Brierley, James D ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 30644475881     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0139-7.50022-3     Document Type: Chapter

References (83)

1. Venkatesh S, Ordonez N, Schultz P, et al. Anaplastic carcinoma of the thyroid. Cancer 1990, 66:321.
2. Tann R, Finlay R, Driscoll D, et al. Anaplastic carcinoma of the thyroid: A 24 year experience. Head Neck 1995, 17:41.
3. Mazzaferri E, Oertel J Pathology and prognosis of thyroid cancer. Surgery of the Thyroid and Parathyroid Glands 1983, 33. Churchill Livingston, New York. E. Kaplan (Ed.).
4. Farnebo L, Tash O, Wallin G Anaplastic giant cell carcinoma of the thyroid. Common Problems in Endocrine Surgery 1989, 33. Yearbook, London. J.A. Van Heerden (Ed.).
5. Norton J, Doppman J, Jensen R Cancer of the endocrine system. Cancer 1989, JB Lippincott, Philadelphia. A. DeVita, S. Hellmann, S. Rosenberg (Eds.).
6. Werner B, Abele J, Alveryd A, et al. Multimodal therapy in anaplastic giant cell thyroid carcinoma. World J Surg 1984, 8:64.
7. Tallroth E, Wallin G, Lundell G, et al. Multimodal treatment in anaplastic giant cell carcinoma. Cancer 1987, 60:1428.
8. McIvor B, Hay I, Giuffrida D, et al. Anaplastic thyroid carcinoma: A 50 year experience at a single institution. Surgery 2001, 130:1028.
9. Nilsson O, Lindeberg J, Zedenius J, et al. Anaplastic giant cell carcinoma of the thyroid gland: Treatment and survival over a 25 year period. World J Surg 1998, 725.
10. Ain K Anaplastic thyroid carcinoma: Behavior, biology, and therapeutic approaches. Thyroid 1998, 8:715.
11. Lundell T, Wahlberg P, Bergenfelz A Anaplastic thyroid carcinoma: Three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002, 86:1848.
12. Busnardo B, Daniele O, Pelizzo M A multimodality therapeutic approach in anaplastic thyroid carcinoma: A study of 39 patients. J Endocrinol Invest. 2000, 23:755.
13. Haigh P, Ituarte P, Wu H, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and radiation is associated with prolonged survival. Cancer 2001, 91:2335.
14. Besic N, Auersperg M, Us-Krasovec M, et al. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 2001, 27:260.
15. Moretti F, Farsetti A, Soddu S, et al. P53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1996, 14:729.
16. Santoro M, Papotti M, Chiappetta G Ret activation and clinicopathological features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 2002, 87:370.
17. Garcia-Rostan G, Tallini G, Herrero A, et al. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999, 59:1811.
18. Osawa H, Asakawa H, Kobayashi T Multistep carcinogenesis in anaplastic thyroid carcinoma. Pathology 2002, 34:94.
19. Komoike Y, Tamaki Y, Sakita I, et al. Comparative genomic hybridization defines frequent loss on 16P in human anaplastic thyroid carcinoma. Int J Oncol 1999, 14:1157.
20. Basolo F, Pisaturo F, Pollina L, et al. N-ras mutation in poorly differentiated thyroid carcinoma: Correlation with metastases and inverse correlation to thyroglobulin expression. Thyroid 2000, 10:19.
21. Postema PT, DeHerder WW, Reubi J Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 1996, 57(Suppl 1):36.
22. LiVolsi VA Surgical Pathology of the Thyroid 1990, WB Saunders, Philadelphia.
23. Rosai J, Carcangiu M, DeLellis R Tumors of the thyroid gland. Atlas of Tumor Pathology 1992, Armed Forces Institute of Pathology, Washington, DC, 3rd series, fascicle 5.
24. Shvero J, Gal R, Avidor I, et al. Anaplastic thyroid carcinoma. Cancer 1988, 62:319.
25. Gaffey M, Lack H, Christ M, Weiss I Anaplastic thyroid carcinoma with osteoclast-like giant cells. Am J Surg Pathol 1991, 15:160.
26. Ordonez N, El-Naggar A, Hickey R, Samaan N Anaplastic thyroid carcinoma. Am J Clin Pathol 1991, 96:15.
27. Carcangiu M, Steeper T, Zampi G, Rosai J Anaplastic thyroid carcinoma. Am J Clin Pathol. 1985, 83:135.
28. Hurlimann J, Gardiol D, Scazziga B Immunohistology ol anaplastic thyroid carcinoma. Histopathology 1987, 11:567.
29. LiVolsi VA, Brooks J, Arendash-Durand B Anaplastic thyroid tumors. J Clin Pathol 1987, 87:434.
30. Pilotti S, Collini P, DelBo R, et al. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. Am J Surg Pathol 1994, 18:1054.
31. Fagin J Genetic basis of endocrine disease. J Clin Endocrinol Metab 1992, 75:1398.
32. Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992, 52:1369.
33. Levine A The p53 tumor-suppressor gene. N Engl J Med 1992, 326:1350.
34. Nigro J, Baker S, Preisinger A, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989, 3412:705.
35. Gaal J, Horvath E, Kovacs K Ultrastructure of two cases of anaplastic giant cell tumor of the human thyroid gland. Cancer 1975, 35:1273.
36. Jao W, Gould V Ultrastructure of anaplastic (spindle and giant cell) carcinoma of the thyroid. Cancer 1975, 35:1280.
37. Asa SL, Dardick I, VanNostrand A, et al. Primary thyroid thymoma: A distinct clinicopathologic entity. Hum Pathol 1988, 19:1463.
38. Carcangiu ML, Zampi G, Rosai J Poorly differentiated ("insular") thyroid carcinoma: A reinterpretation of Langhans' "wuchernde Struma.". Am J Surg Pathol 1984, 8:655.
39. Sakamoto A, Kasai N, Sugano H Poorly differentiated carcinoma of the thyroid: A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 1983, 52:1849.
40. van der Laan F, Freeman JL, Tsang RW, Asa SL The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma: Evidence for dedifferentiation in tumor progression. Endocr Pathol 1993, 4:215.
41. Vogelstein B, Fearon E, Hamilton S, et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988, 319:525.
42. Suarez H, duVillard J, Severino M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990, 5:565.
43. Namba H, Rubin S, Fagin F Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 1990, 4:1474.
44. Junor E, Paul J, Reed N Anaplastic thyroid carcinoma. Eur J Surg Oncol 1992, 18:83.
45. Simpson WJ Anaplastic thyroid carcinoma: A new approach. Can J Surg 1980, 23:125.
46. Kim J, Leiper R Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987, 60:2372.
47. Schlumberger M, Parmentier C, Delisle M, et al. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 1991, 67:564.
48. Tennvall G, Lundell G, Hallquist A, et al. Combined doxorubicin, hyperfractionated radiotherapy and surgery in anaplastic thyroid carcinoma. Cancer 1994, 74:1348.
49. Hoskin P, Harmer C Chemotherapy for thyroid cancer. Radiother Oncol 1987, 10:187.
50. Williams S, Birch R, Einhorn L Phase II evaluation of doxorubicin plus cis platinum in advanced thyroid cancer: Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986, 70:405.
51. Shimaoka K, Schoenfeld D, DeWys W, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985, 56:2155.
52. Wong C, Van Dyk J, Simpson WJ Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1991, 20:3.
53. Sugino K, Ito K, Mimura T, et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002, 131:245.
54. Mitchell G, Huddart R, Harmer C Phase 2 evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1999, 50:33.
55. Ain K, Egorin MJ, DcSimone PA Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion. Thyroid 2000, 10:587.
56. Yeung SC, Xu G, Pan J, et al. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 2000, 60:650.
57. Voigt W, Bulankin A, Muller T, et al. Schedule dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 2000, 6:2087.
58. Pacheco-Ojeda LA, Martinez AL, Alvarez M Anaplastic thyroid carcinoma in Ecuador: Analysis of prognostic factors. Int Surg 2001, 86:117.
59. Sugitani I, Nobukatsu K, Eujimoto Y, Akio Y Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 2001, 25:617.
60. Fiore L, Pollina L, Fontanini G, et al. Cytokine production by new undifferentiated human thyroid carcinoma cell line FBI-1. J Clin Endocrinol Metab 1997, 82:4094.
61. Blagosklonny MV, Giannakakou P, Wojtowicz M, et al. Effects of P53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 1998, 83:2516.
62. Haberkorn U, Altmann A, Jiang S Iodine uptake in human anaplastic thyroid carcinoma cells after transfer of human thyroid peroxidase gene. Eur J Nucl Med 2001, 28:633.
63. Franzen A, Heldin NE BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21 (C1P1) and p27 (KIP1). Biochem Biophys Res Commun 2001, 285:773.
64. Liu W, Asa SL, Fantus IG, et al. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol 2002, 160:511.
65. Dackiw AP, Ezzat S, Haung P, et al. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 2004, 145:5840.
66. Krainberg VL, Williams JM, Cogswell JP, et al. Histone deacetylase inhibitors promote apoptosis in differential cell cycle arrest in anaplastic thyroid cells. Thyroid 2001, 11:315.
67. Kotchetkov R, Cinatl J, Krivtchik AA, et al. Selective activity of BS-RNase against anaplastic thyroid cancer. Anticancer Res 2001, 21:1035.
68. Portella G, Scala S, Vitagliano D, et al. Onyx-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 2002, 87:2525.
69. Yin F, Giuliano AE, VanHerle AJ Signal pathways involved in apigenin inhibition of growth in induction of apoptosis of human anaplastic thyroid cancer cells (ARO). Anticancer Res 1999, 19:4297.
70. Takano T, Hasegawa Y, Miyauchi A, et al. Overexpression of kalphal tubulin mRNA in thyroid anaplastic carcinoma. Cancer Lett 2001, 168:51.
71. Dziba J, Marcinek R, Venkataraman G, et al. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002, 12:1063.
72. Miura D, Wada N, Chin K, et al. Anaplastic thyroid cancer. Thyroid 2003, 13:283.
73. Nikiforova M, Kimura E, Gandhi M, et al. BRAF mutation in thyroid tumors. J Clin Endocrinol Metab 2003, 88:5399.
74. Hunt J, Tometsko N, Livolsi V, et al. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 2003, 12:1559.
75. Ito Y, Yoshida H, Tomoda C, et al. Decreased expression of p107 as correlated with anaplastic transformation in papillary carcinoma of the thyroid. Anticancer Res 2003, 23:3819.
76. Schmidt-Winnenthal F, Weckauf H, Haufe S, et al. Detection and prognosis relevance of cytokeratin 20 in differentiated and anaplastic thyroid carcinoma by RT-PCR. Surgery 2003, 134:964.
77. Rodrigues R, Roque L, Rosa-Santos J, et al. Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinoma. Br J Cancer 2004, 90:492.
78. Onda M, Nagai H, Yoshida H Up-regulation of transcriptional factor B2F1 in papillary and anaplastic thyroid cancer. J Hum Genet 2004, 49:312.
79. Shi Y, Parhar R, Zou F, et al. Gone therapy of anaplastic thyroid carcinoma with a single chain interleukin-12 fusion protein. Hum Genet Ther 2003, 14:1741.
80. Starenki D, Nmba H, Sacnko V, et al. Inhibition of nuclear factor-kappa B cascade potentiates the effect of combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2004, 89:410.
81. Dziba J, Ain K Imatineb meslyate (gleevec:ST1571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. J Clin Endocrinol Metab 2004, 89:2127.
82. Clano M, Calvagno M, Bulotta S, et al. Cytotoxic effects of gemcitabinc loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer 2004, 4:63.
83. Kihara M, Miyauchi A, Yamauchi A, Yokomise A Prognostic factors of anaplastic thyroid carcinoma. Surg Today 2004, 34:394.